Trial Profile
Indacaterol 110µg/ Glycopyrronium 50µg (Ultibro) Versus Tiotropium (Spiriva) Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms RED
- 21 Jan 2019 Status changed from recruiting to completed.
- 19 Mar 2018 Planned End Date changed from 1 Dec 2017 to 16 Jun 2018.
- 19 Mar 2018 Planned primary completion date changed from 1 Mar 2017 to 25 May 2018.